BIO Submits Comments to CMS Regarding its Medicare Program; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Program; Proposed Rule (Protected Classes)

 

March 7, 2014

 

BY ELECTRONIC DELIVERY

 

Marilyn B. Tavenner

Administrator

Centers for Medicare & Medicaid Services

U.S. Department of Health and Human Services

Hubert H. Humphrey Building, Room 445-G

200 Independence Avenue, SW

Washington, DC 20201

 

Re:  Medicare Program; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Program; Proposed Rule [CMS-4159-P]

 

Dear Administrator Tavenner:

 

The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs (the “Proposed Rule”).  BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products.

 

TO VIEW THE FULL COMMENT LETTER, CLICK HERE.